FrancophonIA/ELRC3.0 huggingface dataset:
English: It helps to destroy the patient's existing blood-making cells, resulting in the successful transplantation of new cells, improved survival and a reduced risk of the diseases coming back.
Estonian: See aitab hävitada patsiendi olemasolevad vereloomerakud, mille tulemuseks on uute rakkude edukam siirdamine, paranenud elulemus ja haiguse taastekke väiksem risk.
English: It must also not be used together with the vaccine against yellow fever or vaccines containing live viruses or bacteria.
Estonian: Samuti ei tohi ravimit kasutada koos kollapalavikuvaktsiiniga ja elusviiruseid või elusbaktereid sisaldavate vaktsiinidega.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Tepadina can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Tepadina kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: In children, the daily dose ranges from 125 to 350 mg/m2 given for up to three days before transplantation.
Estonian: Lastel on ööpäevane annus 120-350 mg/m2, mida manustatakse kuni 3 päeva jooksul enne siirdamist.
English: In adults, the daily dose ranges from 120 to 481 mg per square metre (m2) given for up to five days before transplantation.
Estonian: Täiskasvanutel on ööpäevane annus 120-481 mg/m2, mis manustatakse kuni 5 päeva jooksul enne siirdamist.
English: The full EPAR for Tepadina can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Tepadina kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Because the number of patients in the European Union (EU) that undergo this type of conditioning and transplant is low, Tepadina was designated an ‘orphan medicine' (a medicine used in rare diseases) on 29 January 2007.
Estonian: Et sellist ettevalmistavat ravi ja siirdamist vajavate patsientide arv on Euroopa Liidus väike, nimetati Tepadina 29. jaanuaril 2007 harvikravimiks.
English: The Committee decided that, based on available published information, Tepadina's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et avaldatud andmete põhjal on Tepadina kasulikkus suurem kui kaasnevad riskid, ja soovitas anda Tepadina müügiloa.
English: For more information about treatment with Tepadina, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist..
Estonian: Kui vajate Tepadinaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The published studies showed that thiotepa used in combination with other chemotherapy medicines is beneficial to adults and children being treated for blood diseases and solid tumours.
Estonian: Avaldatud uuringud näitasid, et tiotepa koos teiste keemiaravi ravimitega on verehaiguste ja soliidtuumoritega täiskasvanute ning laste ravis kasulik.
English: Thiotepa has been used to prepare patients for transplantation of blood-making cells in the European Union (EU) since the late 1980s.
Estonian: Tiotepat on vereloomerakkude siirdamise ettevalmistamiseks kasutatud Euroopa Liidus alates 1980. aastate lõpust.
English: Tepadina must not be used in women who are pregnant or breast-feeding.
Estonian: Tepadinat ei tohi kasutada raseduse ja imetamise ajal.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tepadina, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Tepadina omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The studies looked at the number of patients with successful transplantations, how long it took for the diseases to come back and how long the patients survived.
Estonian: Nendes uuringutes olid efektiivsuse põhinäitajad eduka siirdamisega patsientide arv, aeg haiguse taastekkimiseni ja patsientide elulemus.
English: It must be given as an infusion into a large vein lasting two to four hours.
Estonian: Tepadinat manustatakse 2-4-tunnise infusioonina suurde veeni.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tepadina.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What is the risk associated with Tepadina?
Estonian: Mis riskid Tepadinaga kaasnevad?
English: The most common side effects seen with Tepadina when used with other medicines are infections, cytopenia (low number of cells in the blood), graft-versus-host disease (when the transplanted cells attack the body), disorders of the gut, haemorrhagic cystitis (bleeding and inflammation in the bladder) and mucosal inflammation (inflammation of the moist body surfaces).
Estonian: Tepadina kõige sagedamad kõrvalnähud kasutamisel koos teiste ravimitega on infektsioonid, tsütopeenia (vererakkude väike sisaldus), siirikkoe puudulikkus ja hülgamine (olukord, kus siiratud rakud ründavad organismi), seedetrakti häired, hemorraagiline tsüstiit (kusepõie verejooks ja põletik) ning limaskesta põletik.
English: Tepadina can be used for transplantation of cells from a donor and for transplantation of cells derived from the patient's own body.
Estonian: Tepadinat tohib kasutada nii doonorilt pärinevate kui ka patsiendi enda rakkude siirdamise korral.
English: This allows new cells to be transplanted, by creating space for the new cells and reducing the risk of rejection.
Estonian: See võimaldab teha ruumi uutele siiratavatele rakkudele ja vähendab ka siiratud rakkude äratõukereaktsiooni riski.
English: Tepadina treatment must be supervised by a doctor who has experience in treatments given before transplantation.
Estonian: Tepadinat tohib kasutada üksnes siirdamiseelsetes ravimeetodites kogenud arsti järelevalve all.
English: The dose of Tepadina depends on the type of blood disease or solid tumour that the patient has and the type of transplantation to be carried out.
Estonian: Tepadina annus sõltub patsiendi verehaiguse või soliidtuumori tüübist ja plaanitava siirdamise iseloomust.
English: This means that they kill cells, especially cells that multiply rapidly, such as cancer or progenitor (or ‘stem') cells (cells that can develop into different types of cell).
Estonian: Need ained on tsütotoksilised, st nad hävitavad rakke, eelkõige kiiresti paljunevaid rakke - näiteks pahaloomulise kasvaja rakke või eellasrakke (tüvirakke, millest tekivad teist tüüpi rakud).
English: • during the treatment of solid tumours when high-dose chemotherapy followed by transplantation of haematopoietic progenitor cells is needed.
Estonian: • soliidtuumorite suureannuselise keemiaravi korral, mille järel on vaja siirata vereloome eellasrakke.
English: • as a ‘conditioning' (preparative) treatment before transplantation of haematopoietic progenitor cells (the cells that make blood cells).
Estonian: • ettevalmistava ravina enne vereloome eellasrakkude (rakud, millest tekivad vererakud) siirdamist.
English: The medicine can only be obtained with a prescription.
Estonian: Tepadina on retseptiravim.
English: This is a summary of the European Public Assessment Report (EPAR) for Tepadina.
Estonian: See on ravimi Tepadina Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Tepadina
Estonian: Muu teave Tepadina kohta
English: The CHMP noted that the active substance in Tepadina, thiotepa, has a well established used.
Estonian: Inimravimite komitee märkis, et Tepadina toimeaine tiotepa kasutus on meditsiiniliselt hästi tõestatud.
English: How has Tepadina been studied?
Estonian: Kuidas Tepadinat uuriti?
English: Tepadina is used with other medicines before transplantation to destroy the abnormal cells and the patient's existing blood-making cells.
Estonian: Tepadinat kasutatakse enne siirdamist koos teiste ravimitega ebanormaalsete rakkude ja patsiendi vereloome eellassrakkude (vererakke tootvate rakkude) hävitamiseks.
English: The active substance in Tepadina, thiotepa, belongs to a group of medicines called ‘alkylating agents'.
Estonian: Tepadina toimeaine tiotepa kuulub alküülivate ainete ravimirühma.
English: Tepadina is a powder that is made up into a solution for infusion (drip into a vein).
Estonian: Tepadina on infusioonilahuse (veeni tilgutatava lahuse) pulber.
English: How is Tepadina used?
Estonian: Kuidas Tepadinat kasutatakse?
English: What is Tepadina used for?
Estonian: Milleks Tepadinat kasutatakse?
English: It contains the active substance thiotepa.
Estonian: Tepadina toimeaine on tiotepa.
English: For the full list of all side effects reported with Tepadina in adults and children, see the package leaflet.
Estonian: Tepadina kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: (including leukaemia) or diseases causing low red blood cell counts (including thalassaemia or sickle-cell anaemia);
Estonian: või erütrotsüütide (vere punaliblede) sisaldust vähendavate haiguste (nt talasseemia või sirprakuline aneemia) tõttu vaja vererakke tootvad rakud asendada;
English: Why has Tepadina been approved?
Estonian: Miks Tepadina heaks kiideti?
English: This type of transplant is used in patients who need to replace their blood-making cells because they have a blood disease such as a cancer of the blood
Estonian: Vereloome eellasrakke siiratakse patsientidele, kellel on verehaiguse (nt verevähi, sh leukeemia)
English: What benefit has Tepadina shown during the studies?
Estonian: Milles seisneb uuringute põhjal Tepadina kasulikkus?
English: The full EPAR for Temozolomide Sandoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Temozolomide Sandozi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The dose of Temozolomide Sandoz depends on body surface area (calculated using the patient's height and weight) and ranges from 75 to 200 mg per square metre, once a day.
Estonian: Temozolomide Sandozi annus oleneb kehapindalast (arvutatakse patsiendi pikkuse ja kehamassi järgi) ning on 75-200 mg/m2 ööpäevas.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Temozolomide Sandoz on 15 March 2010.
Estonian: Euroopa Komisjon andis Temozolomide Sandozi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. märtsil 2010.
English: Temozolomide Sandoz should be taken without food.
Estonian: Temozolomide Sandozit tuleb võtta ilma toiduta.
English: The dose and the number of doses depend on the type of tumour being treated, whether the patient has been treated before, whether Temozolomide Sandoz is being used alone or with other treatments, and how the patient responds to treatment.
Estonian: Annus ja annuste arv sõltuvad ravitava kasvaja liigist, varasemast ravist, sellest, kas Temozolomide Sandozit kasutatakse ainsa raviviisina või koos teistega, ja patsiendi ravivastusest.
English: For more information about treatment with Temozolomide Sandoz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Temozolomide Sandoziga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Because Temozolomide Sandoz is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Temozolomide Sandoz on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Temozolomide Sandoz.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Therefore, the CHMP's view was that, as for Temodal, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Temodali korral, ületab Temozolomide Sandozi kasulikkus sellega kaasnevad riskid.
English: The Committee recommended that Temozolomide Sandoz be given marketing authorisation.
Estonian: Komitee soovitas anda Temozolomide Sandozi müügiloa.
English: The CHMP concluded that, in accordance with EU requirements, Temozolomide Sandoz has been shown to have comparable quality and to be bioequivalent to Temodal.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Temozolomide Sandoz võrdväärne kvaliteet ja bioekvivalentsus ravimiga Temodal.
English: This is a summary of the European Public Assessment Report (EPAR) for Temozolomide Sandoz.
Estonian: See on ravimi Temozolomide Sandoz Euroopa avaliku hindamisaruande kokkuvõte.
English: This means that Temozolomide Sandoz is similar to a ‘reference medicine' already authorised in the European Union (EU) called Temodal.
Estonian: See tähendab, et Temozolomide Sandoz on sarnane võrdlusravimiga Temodal, millel juba on Euroopa Liidus müügiluba.
English: Other information about Temozolomide Sandoz
Estonian: Muu teave Temozolomide Sandozi kohta
English: Because Temozolomide Sandoz is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal.
Estonian: Et Temozolomide Sandoz on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Temozolomide Sandozi bioekvivalentsust võrdlusravimiga Temodal.
English: Temozolomide Sandoz is used first with radiotherapy and then on its own;
Estonian: Temozolomide Sandozit kasutatakse esialgu koos kiiritusraviga ning seejärel ainsa raviviisina;
English: Treatment with Temozolomide Sandoz should be prescribed by a doctor with experience in the treatment of brain tumours.
Estonian: Ravi Temozolomide Sandoziga võib määrata vaid ajukasvajate ravis kogenud arst.
English: Temozolomide Sandoz temozolomide
Estonian: Temozolomide Sandoz temosolomiid
English: Temozolomide Sandoz is a medicine that contains the active substance temozolomide.
Estonian: Temozolomide Sandoz on ravim, mis sisaldab toimeainena temosolomiidi.
English: Patients may also need to take medicines to prevent vomiting before taking Temozolomide Sandoz.
Estonian: Enne Temozolomide Sandozi võtmist võib olla vaja võtta oksendamist ennetavaid ravimeid.
English: Why has Temozolomide Sandoz been approved?
Estonian: Miks Temozolomide Sandoz heaks kiideti?
English: What is Temozolomide Sandoz?
Estonian: Mis on Temozolomide Sandoz?
English: Temozolomide Sandoz is a ‘generic medicine'.
Estonian: Temozolomide Sandoz on geneeriline ravim.
English: The active substance in Temozolomide Sandoz, temozolomide, belongs to a group of anticancer medicines called alkylating agents.
Estonian: Temozolomide Sandozi toimeaine temosolomiid kuulub alküleerivateks aineteks nimetatavate vähiravimite rühma.
English: How has Temozolomide Sandoz been studied?
Estonian: Kuidas Temozolomide Sandozit uuriti?
English: Temozolomide Sandoz is an anticancer medicine.
Estonian: Temozolomide Sandoz on vähiravim.
English: How does Temozolomide Sandoz work?
Estonian: Kuidas Temozolomide Sandoz toimib?
English: Temozolomide Sandoz is used on its own in these patients.
Estonian: Nendel patsientidel kasutatakse Temozolomide Sandozit ainsa raviviisina.
English: How is Temozolomide Sandoz used?
Estonian: Kuidas Temozolomide Sandozit kasutatakse?
English: What is Temozolomide Sandoz used for?
Estonian: Milleks Temozolomide Sandozit kasutatakse?
English: What are the benefit and risk of Temozolomide Sandoz?
Estonian: Milles seisneb Temozolomide Sandozi kasulikkus ja mis riskid ravimiga kaasnevad?
English: From a microbiological point of view the product should be used immediately.
Estonian: Mikrobioloogilisest vaatepunktist tuleb toode kohe ära kasutada.
English: • if you have or have had any heart problems.
Estonian: • kui teil on või on olnud südameprobleemid;
English: ** From post-marketing experience
Estonian: ** Turuletulekujärgse kogemuse põhjal
English: Date of first authorisation: 31 July 2009 Date of latest renewal: 11 April 2014
Estonian: Müügiloa esmase väljastamise kuupäev: 31. juuli 2009 Müügiloa viimase uuendamise kuupäev: 11. aprill 2014
English: Tell your doctor:
Estonian: Informeerige oma arsti:
English: Elderly patients (> 65 years old)
Estonian: Eakad (> 65-aastased)
English: A risk to the suckling child cannot be excluded.
Estonian: Võimalikku ohtu imetatavale lapsele ei saa välistada.
English: If you want to know more about G-CSF ask your doctor and read the corresponding package leaflet.
Estonian: Kui te tahate G-CSF-i kohta rohkem teada saada, siis küsige oma arstilt ja lugege vastavat pakendi infolehte.
English: Ideal body weight can be determined using the following equations:
Estonian: Ideaalkaalu võib välja arvutada järgmiste valemite abil:
English: Other medicines and Mozobil
Estonian: Muud ravimid ja Mozobil
English: The pharmacist will throw away medicines you no longer use.
Estonian: Küsige oma apteekrilt, kuidas visata ära ravimeid, mida te enam ei kasuta.
English: Each vial is intended for single use only.
Estonian: Iga viaal on mõeldud ühekordseks kasutamiseks.
English: • if you are allergic to plerixafor or any of the other ingredients of this medicine (listed in section 6).
Estonian: • kui olete pleriksafoori või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline.
English: G-CSF will help Mozobil to work properly in your body.
Estonian: G-CSF aitab Mozobil'il teie organismis õigesti toimida.
English: * The frequency of allergic reactions presented is based on adverse reactions that occurred in the oncology studies (679 patients).
Estonian: * Tabelis esitatud allergiliste reaktsioonide esinemissagedus põhineb onkoloogilistes uuringutes (679 patsienti) ilmnenud kõrvaltoimetel.
English: Pharmacotherapeutic group: Other immunostimulants; ATC code: L03AX16
Estonian: Farmakoterapeutiline rühm: teised immunostimulaatorid; ATC-kood: L03AX16
English: After opening the vial, Mozobil should be used immediately.
Estonian: Pärast viaali avamist tuleb Mozobil kohe ära kasutada.
English: Appropriate precautions should be taken because of the potential for these reactions.
Estonian: Nende reaktsioonide tekkevõimaluse tõttu peab rakendama vastavaid ettevaatusabinõusid.
English: Please inform your doctor immediately if you experience chest discomfort.
Estonian: Palun teavitage kohe oma arsti, kui te tunnete ebamugavustunnet rindkeres.
English: It is important to tell your doctor if you are, think you may be or are planning to become pregnant.
Estonian: Teavitage kindlasti oma arsti, kui te olete rase, arvate, et võite olla rase või plaanite rasestuda.
English: Clinical data with this dose adjustment are limited.
Estonian: Kliinilised andmed sellise annuse kohandamise kohta on piiratud.
English: In a few cases, enough stem cells may not be collected, and the collection attempt will be stopped.
Estonian: Üksikjuhtudel ei ole võimalik koguda piisavat kogust tüvirakke ja kogumisprotseduur katkestatakse.
English: • Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Estonian: • kui muudetakse riskijuhtimissüsteemi, eriti kui saadakse uut teavet, mis võib oluliselt mõjutada riski/kasu suhet, või kui saavutatakse oluline ravimiohutuse või riski minimeerimise) eesmärk.
English: Studies in animals have shown teratogenicity (see section 5.3).
Estonian: Loomkatsed on näidanud teratogeensust (vt lõik 5.3).
English: Your doctor may perform regular blood tests to monitor your blood cell count.
Estonian: Teie arst võib teile määrata korrapäraselt vereproove, et kontrollida vererakkude arvu.
English: Systemic Exposure (AUC0-10h) comparisons of fixed and weight based regimens
Estonian: Süsteemse saadavuse (AUC0-10h) võrdlus kindlaksmääratud ja kehakaalul põhineva annustamisskeemi korral
English: female (kg):
Estonian: naised (kg):
English: In some instances, these patients experienced an increase in the number of circulating leukaemia cells.
Estonian: Mõnedel juhtudel täheldati neil patsientidel tsirkuleerivate leukeemiliste rakkude arvu suurenemist.
English: Adverse reactions are listed by System Organ Class and frequency.
Estonian: Kõrvaltoimed on klassifitseeritud organsüsteemi klasside kaupa ja esinemissageduse alusel.
English: Fertility The effects of plerixafor on male and female fertility are not known (see section 5.3).
Estonian: Fertiilsus Pleriksafoori mõju mehe ja naise fertiilsusele ei ole teada (vt lõik 5.3).
English: • if you have high white blood cell counts.
Estonian: • kui teil on suur vere valgeliblede arv;
English: CD34+ cells mobilised by plerixafor are functional and capable of engraftment with long-term repopulating capacity.
Estonian: Pleriksafoori poolt mobiliseeritud CD34+ rakud on funktsioneerivad ja siirdamisvõimelised ning pikaaegse repopulatsioonivõimega.
English: Mozobil may influence the ability to drive and use machines.
Estonian: Mozobil võib mõjutada autojuhtimise ja masinate käsitsemise võimet.
English: male (kg):
Estonian: mehed (kg):
English: Paediatric (1 to less than 18 years)
Estonian: Lapsed (vanuses 1 kuni 18 aastat)
English: Treatment lasts 2 to 4 consecutive days (in some cases up to 7 days), until enough stem cells have been collected for your transplant.
Estonian: Ravi manustatakse 2…4 järjestikusel päeval (mõnel juhul kuni 7 järjestikusel päeval), kuni on õnnestunud koguda siirdamiseks piisav kogus tüvirakke.
English: The dose of haematopoietic stem cells used for each transplant was determined by the investigator and all haematopoietic stem cells that were collected were not necessarily transplanted.
Estonian: Hemopoeetiliste rakkude doosi igaks transplantatsiooniks määras kindlaks uurija ja kõiki kogutud hemopoeetilisi rakke ei kasutatud tingimata transplantatsiooniks.
English: Please tell your doctor immediately if
Estonian: Palun informeerige kohe oma arsti:
English: Frequencies are defined according to the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Estonian: Esinemissagedused on esitatud järgmise kokkuleppelise klassifikatsiooni alusel: väga sage (≥ 1/10); sage (≥ 1/100 kuni < 1/10); aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10000 kuni < 1/1000); väga harv (< 1/10000); teadmata (ei saa hinnata olemasolevate andmete alusel).
English: If you have moderate or severe kidney problems, your doctor will reduce the dose.
Estonian: Mõõduka või raske neerupuudulikkuse korral vähendab arst annust.
English: Women of childbearing potential Women of childbearing potential have to use effective contraception during treatment.
Estonian: Rasestumisvõimelised naised Rasestumisvõimelised naised peavad ravi ajal kasutama efektiivset rasestumisvastast meetodit.
English: In vitro tests showed that plerixafor was not metabolised by P450 CYP enzymes, did not inhibit or induce P450 CYP enzymes.
Estonian: In vitro testid näitasid, et pleriksafoor ei metaboliseerunud P450 CYP ensüümide vahendusel, ei inhibeerinud ega indutseerinud P450 CYP ensüüme.
English: Days
Estonian: Päevad